UBS raises Abbvie stock price target to $295 on strong quarter

Cantor Fitzgerald kept its Overweight rating on AbbVie (ABBV) but increased its price target to $325 from $290, suggesting a 10.2% upside from the last close. Recent analyst targets for AbbVie range from $275 to $325.

AbbVie (ABBV) reported positive Phase 2 results for ABBV-466, a combination therapy for Crohn’s disease. The treatment met primary endpoints, with 40.5% of patients achieving remission at week 24. Analysts view the data positively, suggesting it could extend Skyrizi’s lifecycle. AbbVie’s stock has risen 30% year-to-date, supported by strong free cash flow and dividend growth.

AbbVie (ABBV) reports positive Phase 2 trial results for ABBV-466, a combination of Skyrizi and trosunilimab, showing higher remission rates in Crohn's patients. Analysts from BMO and RBC highlight the potential for ABBV-466 to extend AbbVie's success. ABBV stock is up 30% year-to-date, with a market cap of $521.11B.

Wells Fargo raised its price target for AbbVie (NYSE:ABBV) to $340 from $300, citing a strong pipeline and encouraging demand for key drugs. The stock is near its 52-week high. AbbVie reported Q3 2026 earnings of $3.82 per share, beating estimates, and raised its full-year outlook. UBS also increased its price target to $295.

AbbVie (ABBV) raised its 2026 adjusted EPS guidance to $13.95-$13.99 and increased its quarterly dividend by 5.2% to $1.82. Q3 revenue was $17.404B, up 10.3%, with Skyrizi and Rinvoq sales growing over 22%. The stock hit a record $294.89. Adjusted payout ratio is around 52%, expected to drop to 40% by 2028.

AbbVie reported Q3 2026 revenue of $17.4B, up 10.3% YoY, meeting expectations. Adjusted earnings were $3.82/share, exceeding forecasts. Operating margin rose to 36%. The company raised its full-year earnings guidance to a midpoint of $13.97/share, citing strong performance and recent acquisitions.